hydrocortisone (centrally authorised products for adrenal insufficiency, paediatric use only)
As the list published 23 Sept 2026 has it, binding since 27 Sept 2024. Each entry binds six months after its own publication date (Article 107c(7) of Directive 2001/83/EC).
What the list says
- EU reference date
- 9 Feb 2018
- PSUR frequency
- 3 years
- Data lock point
- 8 Aug 2026
- Submission date
- 6 Nov 2026
- Next data lock point
- Not stated
- Next submission date
- Not stated
- Products covered
- Centrally authorised (CAP)
Are PSURs required for products referred to in Articles 10(1), 10a and 16a of Directive 2001/83/EC?
No — the list does not require PSURs for these products.
The list asks this as one question for Articles 10(1), 10a and 16a together, and does not answer it for Article 14 at all. A PSUR may in any case be required at the request of a competent authority or as a condition of the marketing authorisation.
Notes in the list
PSUR frequency amended and DLP updated on 27/03/2024
Track dates like these for your own products: a sample workspace, read-only, no account needed.
Try the demoThe next three reports
- Data lock point 8 Aug 2026Submission by 6 Nov 2026
- Data lock point 8 Aug 2029Submission by 6 Nov 2029
- Data lock point 8 Aug 2032Submission by 6 Nov 2032
Counted from the data lock point the list gives, on the cycle it states: the submission date is 90 days after the data lock point — 70 days for a cycle of twelve months or less, 90 days for a longer one, as GVP Module VII sets out.
In earlier versions of the list
EMA/630645/2012 Rev.164 · published 23 Sept 2026
hydrocortisone (centrally authorised products for adrenal insufficiency, paediatric use only) — every 3 years, data lock point 8 Aug 2026
EMA/630645/2012 Rev.156 · published 4 Feb 2026
hydrocortisone (centrally authorised products for adrenal insufficiency, paediatric use only) — every 3 years, data lock point 8 Aug 2026
Source: European Medicines Agency, list of EU reference dates and frequency of submission of periodic safety update reports, EMA/630645/2012 Rev.164, published 23 Sept 2026. Open the published file
Kreastel is a planning and oversight aid for pharmacovigilance obligations. It tracks dates like these for a marketing authorisation holder's own products.
Report a discrepancy — if this page and the published file disagree, the file is right and we want to know.